37 results
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
17 Jan 24
Current report (foreign)
4:30pm
the potential long-term value of the successful execution of Gracell’s current strategy as an independent public company;
the fact that under the terms … , and long-term strategies to increase shareholder value, including seeking opportunities to fund the clinical development and commercialization of GC012F
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
14 Nov 23
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
6:04am
resistance to immunosuppressive TME and maintained long-term proliferation and cytotoxicity both in vitro and in vivo. In mouse models, SMART CART cells … and current portion of long-term borrowings of RMB69.6 million (US$9.5 million) and long-term borrowings of RMB33.5 million (US$4.6 million).
Net loss
F-3/A
GRCL
Gracell Biotechnologies Inc
12 Sep 23
Shelf registration (foreign) (amended)
4:12pm
amounts)
Actual
As Adjusted
Cash and cash equivalents
Long-term borrowings
Equity:
Ordinary shares
Additional paid-in capital
Accumulated other
F-3
GRCL
Gracell Biotechnologies Inc
24 Aug 23
Shelf registration (foreign)
4:03pm
amounts)
Actual
As Adjusted
Cash and cash equivalents
Long-term borrowings
Equity:
Ordinary shares
Additional paid-in capital
Accumulated other
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
14 Aug 23
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:52pm
Current portion of long-term borrowings (including current portion of long-term borrowings of the consolidated VIEs without recourse to the Company … , 2022 and June 30, 2023, respectively)
Long-term borrowings (including long-term borrowings of the consolidated VIEs without recourse to the Company
6-K
EX-99.2
p4pyq05u
7 Aug 23
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
8:07am
6-K
EX-99.1
x0ho59n0
5 Jun 23
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
6:14am
6-K
EX-99.1
n4em aii21ez0u
16 May 23
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
6:08am
6-K
EX-99.1
mijyvi
16 Nov 22
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results
6:01am
6-K
EX-99.1
biy zn7eo80a14q1ai3
15 Aug 22
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:11pm
6-K
EX-99.1
mejzep8tvhd8uvdo
15 Aug 22
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
8:16am
F-3/A
rdk3 ir5fdv0sjv
17 Jun 22
Shelf registration (foreign) (amended)
9:10am
F-3/A
rdifxyot
19 May 22
Shelf registration (foreign) (amended)
4:03pm
6-K
EX-99.1
1xjx85rjbw d1
17 May 22
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results
6:13am
F-3
71xqg
28 Apr 22
Shelf registration (foreign)
5:06pm
6-K
EX-99.1
7u3k9q 6o9gdardr
22 Nov 21
Current report (foreign)
4:06pm
6-K
EX-99.1
fcel7aiw xhd5qy
16 Nov 21
Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update
6:06am
6-K
EX-99.1
5og99ggfzqdeyce4jl
18 Aug 21
Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update
7:42am